AU2016408376B2 - Composition of probiotics and digestive enzymes and method of preparing and using the same - Google Patents

Composition of probiotics and digestive enzymes and method of preparing and using the same Download PDF

Info

Publication number
AU2016408376B2
AU2016408376B2 AU2016408376A AU2016408376A AU2016408376B2 AU 2016408376 B2 AU2016408376 B2 AU 2016408376B2 AU 2016408376 A AU2016408376 A AU 2016408376A AU 2016408376 A AU2016408376 A AU 2016408376A AU 2016408376 B2 AU2016408376 B2 AU 2016408376B2
Authority
AU
Australia
Prior art keywords
billion cfu
bifidobacterium
probiotic
lactobacillus
cfu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016408376A
Other languages
English (en)
Other versions
AU2016408376A1 (en
Inventor
Kim SHAFER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2016408376A1 publication Critical patent/AU2016408376A1/en
Application granted granted Critical
Publication of AU2016408376B2 publication Critical patent/AU2016408376B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01008—Endo-1,4-beta-xylanase (3.2.1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22032—Stem bromelain (3.4.22.32)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01026—Beta-fructofuranosidase (3.2.1.26), i.e. invertase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01108—Lactase (3.2.1.108)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22002—Papain (3.4.22.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2016408376A 2016-05-24 2016-05-24 Composition of probiotics and digestive enzymes and method of preparing and using the same Ceased AU2016408376B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/033976 WO2017204788A1 (en) 2016-05-24 2016-05-24 Composition of probiotics and digestive enzymes and method of preparing and using the same

Publications (2)

Publication Number Publication Date
AU2016408376A1 AU2016408376A1 (en) 2019-01-17
AU2016408376B2 true AU2016408376B2 (en) 2020-10-22

Family

ID=60411761

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016408376A Ceased AU2016408376B2 (en) 2016-05-24 2016-05-24 Composition of probiotics and digestive enzymes and method of preparing and using the same

Country Status (12)

Country Link
US (1) US20200323929A1 (https=)
EP (1) EP3463404A4 (https=)
JP (1) JP2019516775A (https=)
KR (1) KR102380198B1 (https=)
CN (1) CN109451727A (https=)
AU (1) AU2016408376B2 (https=)
BR (1) BR112018074355A2 (https=)
CA (1) CA3025512A1 (https=)
IL (1) IL263238A (https=)
MX (1) MX2018014500A (https=)
RU (1) RU2018144897A (https=)
WO (1) WO2017204788A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3055915A1 (en) * 2017-03-10 2018-09-13 Biohm Health Llc Compositions and methods for disrupting biofilms of pathogenic bacteria or fungi
WO2019169179A1 (en) * 2018-02-28 2019-09-06 Shafer Kim Augmenting efficacy of cancer therapies using probiotic based compositions
US20210030818A1 (en) * 2018-03-09 2021-02-04 Biohm Health Llc Compositions for use in balancing microbiome
CN109528776A (zh) * 2018-06-08 2019-03-29 广东益可维健康科技有限公司 一种预防治疗口腔疾病的复合益生菌含片及其制备方法
CN109566935A (zh) * 2018-12-06 2019-04-05 张秋环 综合益生菌复合粉固体饮料的制备方法
TWI740101B (zh) * 2019-02-12 2021-09-21 大江生醫股份有限公司 降膽固醇之益生菌株的用途
KR102119133B1 (ko) 2019-05-02 2020-06-26 선정완 유산균 분말 및 노니 분말을 포함하는 프로바이오틱스 조성물
KR102124474B1 (ko) * 2019-08-30 2020-06-19 주식회사 에이치이엠 Pmas방법을 이용한 개인 맞춤형 장내 환경 개선 물질 스크리닝 방법
ES3013459T3 (en) 2019-08-30 2025-04-14 Hem Pharma Inc Method for screening personalized gut environment-improving substance using pmas process
KR102335928B1 (ko) * 2019-10-02 2021-12-08 한국생명공학연구원 비만의 예방, 치료 또는 개선용 조성물
CN111213885A (zh) * 2020-01-20 2020-06-02 齐海心 一种具有调节血脂功效的益生菌组合物及其制备方法与应用
TW202203950A (zh) * 2020-03-30 2022-02-01 香港商香港微生物菌群創新中心有限公司 微生物在調節體重和膽固醇水準中的用途
CN111558033A (zh) * 2020-05-14 2020-08-21 广州中昱医学生物科技有限公司 一种口腔清洁组合物及其应用
CN112021575A (zh) * 2020-09-17 2020-12-04 泉州亚林新材料科技有限公司 一种益生菌组合物及其制备方法
KR20230156825A (ko) * 2021-01-19 2023-11-14 에이티알 쓰라이브 엘엘씨 성인 영양을 위한 우유와 효소의 조성물
CN113244408A (zh) * 2021-06-02 2021-08-13 河北源民生物科技有限公司 一种适用于肠胃的益生菌组合物
JP2023159522A (ja) * 2022-04-20 2023-11-01 国立大学法人 和歌山大学 短鎖脂肪酸産生促進用組成物
CN115025132B (zh) * 2022-06-09 2024-01-30 康永波 一种合生元组合物及其制备方法和应用
CN116042486B (zh) * 2023-02-22 2024-11-08 高邮市人民医院 一种用于治疗动脉粥样硬化的复合菌制剂
WO2025076281A1 (en) * 2023-10-06 2025-04-10 Biohm Health Inc. Microbiome modulating formula for menopausal-aged women

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015100952A4 (en) * 2014-07-17 2015-08-20 Pharm-A-Care Laboratories Pty Ltd Probiotic- and enzyme-containing compositions and uses thereof
US20150250835A1 (en) * 2014-03-07 2015-09-10 Genmont Biotech Inc. Composition and method of lactobacillus reuteri gmnl-89 in treating type 2 diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432097B2 (en) * 1997-08-13 2008-10-07 Verenium Corporation Phytases, nucleic acids encoding them and methods of making and using them
US6436451B1 (en) * 1999-03-26 2002-08-20 Eggland's Best, Inc. Method of reducing cholesterol in chicken eggs
US6368617B1 (en) * 2001-05-15 2002-04-09 Reliv' International, Inc. Dietary supplement
US20040071685A1 (en) * 2002-10-09 2004-04-15 Devin Houston Compositions and methods for increasing the bioavailability of plant polyphenols
GB2465814B (en) * 2008-06-19 2011-10-26 Tarig Sayed Mustafa Arbab Method,composition and device for the treatment of enzymes and saccharides disorders
US8257694B2 (en) * 2009-05-14 2012-09-04 Product Partners, Llc Nutritional compositions for reducing oxidative damage
BR112012024674B1 (pt) * 2010-04-26 2019-07-02 Novozymes A/S Grânulo, e, composição de detergente granular
WO2015172191A1 (en) * 2014-05-12 2015-11-19 Medlab Ip Pty Ltd Probiotic compositions and uses thereof for treatment of obesity-related disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150250835A1 (en) * 2014-03-07 2015-09-10 Genmont Biotech Inc. Composition and method of lactobacillus reuteri gmnl-89 in treating type 2 diabetes
AU2015100952A4 (en) * 2014-07-17 2015-08-20 Pharm-A-Care Laboratories Pty Ltd Probiotic- and enzyme-containing compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAILY BODY RESTORE, LLC, ‘Daily Body Restore Probiotic Supplement with Digestive Enzymes’, 7 August 2012, <URL: https://www.amazon.com/Restore-Probiotic-Supplement-Digestive-Capsules/dp/B005GLM9LQ> *

Also Published As

Publication number Publication date
CN109451727A (zh) 2019-03-08
BR112018074355A2 (pt) 2019-03-06
IL263238A (en) 2018-12-31
RU2018144897A3 (https=) 2020-06-25
KR102380198B1 (ko) 2022-03-29
AU2016408376A1 (en) 2019-01-17
WO2017204788A1 (en) 2017-11-30
JP2019516775A (ja) 2019-06-20
CA3025512A1 (en) 2017-11-30
EP3463404A4 (en) 2020-03-11
KR20190015718A (ko) 2019-02-14
US20200323929A1 (en) 2020-10-15
RU2018144897A (ru) 2020-06-25
EP3463404A1 (en) 2019-04-10
MX2018014500A (es) 2019-04-15

Similar Documents

Publication Publication Date Title
AU2016408376B2 (en) Composition of probiotics and digestive enzymes and method of preparing and using the same
JP6027491B2 (ja) 腎臓機能を増大させるための組成物および方法
EP3344267B1 (en) Bifidobacterium longum for use in treating or preventing major depressive disorder
Delgado et al. The putative effects of prebiotics as immunomodulatory agents
US11166992B2 (en) Composition for use in the therapy of lactose intolerance or conditions arising from lactase deficiency
KR20210013352A (ko) 비만 및 비만 관련 질환을 치료하기 위한 프로바이오틱 조성물 및 방법
Goto et al. Effects of fructo-oligosaccharide on DSS-induced colitis differ in mice fed nonpurified and purified diets
CN106974262A (zh) 肠道益生杆菌在治疗和预防肥胖及其相关疾病中的应用
JP7724223B2 (ja) 抗酸化剤として使用するためのプロバイオティクス組成物
Vinayak et al. Prebiotics for probiotics
EP3889250A1 (en) Phascolarctobacterium faecium for use in the prevention and treatment of obesity and its comorbidities
KR20240167863A (ko) 알코올 분해 조성물 및 그의 용도
Sarojini Gut Microbes: The Miniscule Laborers in the Human Body
CN106974940B (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
US12257271B2 (en) Holdermanella sp. bacterium and use thereof
Code Human strain probiotic to support intestinal health in adults and children
KR20250157969A (ko) 고양이 비만 예방 또는 치료용 조성물 및 이의 용도
CN106974939A (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
JP2025519402A (ja) ビタミンＣ及びビフィドバクテリウム・アニマリス亜種ラクティス（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ａｎｉｍａｌｉｓ ｓｓｐ．ｌａｃｔｉｓ）を含む組み合わせ
RU2571495C1 (ru) Способ лечения больных дисбактериозом кишечника
Cuoco Effect of exogenous β-galactosidase in patients with lactose malabsorption and intolerance: a crossover double-blind placebo-controlled study
Lenard Optimizing digestive health:(and why most probiotics fail to work)
HK1239568A (en) Application of thick-wall fungus probiotics in treatment and prevention of obesity and related diseases
HK1239568A1 (en) Application of thick-wall fungus probiotics in treatment and prevention of obesity and related diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired